PET Amyloid Analyses

Frey, Kirk A.; Koeppe, Robert A.

doi:10.2967/jnumed.116.173989

Cited by 3 publications

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Positron emission tomography (PET) probes have been proposed as tools to facilitate in vivo assessment of islet morphology and to evaluate changes in islet structure over time [17–19]. Many of these probes are directed at beta cell biomarkers such as the glucagon-like peptide-1 (GLP-1) receptor and glucokinase, with the intent to quantify beta cell mass [17,20].…”

Section: Introductionmentioning

confidence: 99%

Use of the PET ligand florbetapir for in vivo imaging of pancreatic islet amyloid deposits in hIAPP transgenic mice

et al. 2018

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Use of the PET ligand florbetapir for in vivo imaging of pancreatic islet amyloid deposits in hIAPP transgenic mice

et al. 2018

View full text Add to dashboard Cite

show abstract

Use of 55 PET radiotracers under approval of a Radioactive Drug Research Committee (RDRC)

Jackson

Lee

Sowa

et al. 2020

EJNMMI radiopharm. chem.

Self Cite

View full text Add to dashboard Cite

Background In the US, EU and elsewhere, basic clinical research studies with positron emission tomography (PET) radiotracers that are generally recognized as safe and effective (GRASE) can often be conducted under institutional approval. For example, in the United States, such research is conducted under the oversight of a Radioactive Drug Research Committee (RDRC) as long as certain requirements are met. Firstly, the research must be for basic science and cannot be intended for immediate therapeutic or diagnostic purposes, or to determine the safety and effectiveness of the PET radiotracer. Secondly, the PET radiotracer must be generally recognized as safe and effective. Specifically, the mass dose to be administered must not cause any clinically detectable pharmacological effect in humans, and the radiation dose to be administered must be the smallest dose practical to perform the study and not exceed regulatory dose limits within a 1-year period. In our experience, the main barrier to using a PET radiotracer under RDRC approval is accessing the required information about mass and radioactive dosing. Results The University of Michigan (UM) has a long history of using PET radiotracers in clinical research studies. Herein we provide dosing information for 55 radiotracers that will enable other PET Centers to use them under the approval of their own RDRC committees. Conclusions The data provided herein will streamline future RDRC approval, and facilitate further basic science investigation of 55 PET radiotracers that target functionally relevant biomarkers in high impact disease states.

show abstract

Chemokine Like Receptor-1 (CMKLR-1) Receptor: A Potential Therapeutic Target in Management of Chemerin Induced Type 2 Diabetes Mellitus and Cancer

Perumalsamy

Zin

Widodo

et al. 2017

CPD

View full text Add to dashboard Cite

show abstract

PET Amyloid Analyses

Cited by 3 publications

References 6 publications

Use of the PET ligand florbetapir for in vivo imaging of pancreatic islet amyloid deposits in hIAPP transgenic mice

Use of the PET ligand florbetapir for in vivo imaging of pancreatic islet amyloid deposits in hIAPP transgenic mice

Use of 55 PET radiotracers under approval of a Radioactive Drug Research Committee (RDRC)

Chemokine Like Receptor-1 (CMKLR-1) Receptor: A Potential Therapeutic Target in Management of Chemerin Induced Type 2 Diabetes Mellitus and Cancer

Contact Info

Product

Resources

About